Archives

STAT+: Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk

In the latest fracas over the burgeoning market for weight loss drugs, a compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients. Strive Specialties claimed the drugmakers entered into exclusive agreements with telehealth providers, which were then barred from working with compounders; […]

Celltrion to internalize U.S. production with $18B investment in New Jersey facility

Celltrion CEO Seo Jin-seok delivers a keynote speech on the company’s future road map at the 44th J.P. Morgan Health Care Conference held in San Francisco on Jan.13. [CELLTRION]   SAN FRANCISCO — Celltrion plans to invest $18 billion over the next decade in its recently acquired U.S. manufacturing facility in Branchburg, New Jersey, expanding […]

[Review] Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, […]

GLP-1 obesity drugs cleared of suicide warning

Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S. FDA is acknowledging that the drugs don’t have the same risk seen with older weight-loss medicines. Citing its post-market evaluation that found no increased risk of suicidal ideation or behavior, the U.S. FDA is requesting that the risk be removed from […]